Minor/Significance Unknown. Use Caution/Monitor.verapamil will increase the level or effect of cortisone by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Use Caution/Monitor. Potential for increased toxicity. A systematic review and meta-analysis of randomized controlled trials", "Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis", "Effects of Statins on Memory, Cognition, and Brain Volume in the Elderly", "Atorvastatin: A medicine used to lower cholesterol", "Atorvastatin Use Associated With Acute Pancreatitis: A Case-Control Study in Taiwan", "Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs", "Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia", "Independent, reliable, relevant and respected", "Efficacy and safety of rosuvastatin in treatment of dyslipidemia", "Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association", "Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin", "Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily", "Update on the efficacy of statin treatment in acute coronary syndromes", "High-dose statins should only be used in atherosclerotic strokes", "Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review", "Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)", "An association study of 43 SNPs in 16 candidate genes with atorvastatin response", "Fig. PRECAUTIONS: Before taking verapamil, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. miconazole vaginal will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)verapamil increases effects of aspirin by unknown mechanism. if such events occur, consider further dose reduction of calcium channel blocker or switching to alternative to calcium channel blocker m channel blocker dose if necessary. Minor/Significance Unknown. phentolamine and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)verapamil, sotalol. Use Caution/Monitor. Modify Therapy/Monitor Closely. verapamil will increase the level or effect of vincristine liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. It is taken by mouth.. Common side effects include abdominal pain, nausea, headaches, and muscle pains. verapamil will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Monitor Closely (2)verapamil will increase the level or effect of estradiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Minor (1)verapamil will increase the level or effect of caffeine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor. Either increases toxicity of the other by Other (see comment). Potential for increased risk of myopathy/rhabdomyolysis. Doing so can release all of the drug at once, increasing the risk of side effects. Avoid or Use Alternate Drug. verapamil increases levels of berotralstat by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. restrictions. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)verapamil will increase the level or effect of neomycin PO by P-glycoprotein (MDR1) efflux transporter. DHEA, herbal will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. It is taken by mouth. Consider decreasing dosage of antihypertensive agent. Minor/Significance Unknown. Minor/Significance Unknown. TIMP1 (TIMP Metallopeptidase Inhibitor 1) is a Protein Coding gene. Use Caution/Monitor. Monitor Closely (1)verapamil will increase the level or effect of desipramine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)verapamil will increase the level or effect of alprazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. [76] In contrast to some other statins, atorvastatin does not interact with warfarin concentrations in a clinically meaningful way (similar to pitavastatin). Minor/Significance Unknown. Monitor Closely (1)cobicistat will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Monitor plasma levels when used concomitantlySerious - Use Alternative (1)carbamazepine will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. terazosin and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor. Use Caution/Monitor.Serious - Use Alternative (1)verapamil will increase the level or effect of silodosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. verapamil will increase the level or effect of ramelteon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)verapamil will increase the level or effect of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. You may report side effects to Health Canada at 1-866-234-2345. Minor/Significance Unknown. Either increases toxicity of the other by Other (see comment). Monitor Closely (1)metronidazole will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)verapamil will increase the level or effect of buprenorphine, long-acting injection by affecting hepatic/intestinal enzyme CYP3A4 metabolism. calcium citrate decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor. verapamil will increase the level or effect of vinblastine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvY2FsYW4tc3ItaXNvcHRpbi1zci12ZXJhcGFtaWwtMzQyMzgw, View explanations for tiers and After discontinuing the inhibitor for 3-5 elimination half-lives, resume previous encorafenib dose. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Avoid or Use Alternate Drug. Because of the potential additive effects on heart rate, siponimod should generally not be initiated in patients taking QT prolonging drugs with known arrhythmogenic properties, heart rate lowering calcium channel blockers, or other drugs that may decrease heart rate. Avoid or Use Alternate Drug. If not feasible, avoid use of abametapir. Monitor therapeutic drug concentrations, as indicated, or consider reducing the dosage of the P-gp substrate and titrate to clinical effect.Serious - Use Alternative (1)verapamil increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with verapamil. Modify Therapy/Monitor Closely. Modify Therapy/Monitor Closely. Monitor Closely (1)phenytoin will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Hepatic Impairment: Increased drug levels can be seen in patients with advanced cirrhosis; specific precaution should be used in patients with chronic. Monitor heart rate in patients receiving concomitant verapamil and clonidine. Use Caution/Monitor. Modify Therapy/Monitor Closely. Avoid or Use Alternate Drug. [114] Initially, generic atorvastatin was manufactured only by Watson Pharmaceuticals and India's Ranbaxy Laboratories. verapamil will increase the level or effect of cortisone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil will increase the level or effect of methadone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairment. [110][111], Atorvastatin calcium tablets are sold under the brand name Lipitor. Avoid or Use Alternate Drug. verapamil will increase the level or effect of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. diltiazem will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments. Use Caution/Monitor. Minor (1)treprostinil increases effects of verapamil by pharmacodynamic synergism. verapamil will increase the level or effect of posaconazole by P-glycoprotein (MDR1) efflux transporter. Can increase risk of bradycardia. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Use Caution/Monitor. [90][91] The polymorphisms that showed genome wide significance in Caucasian population were the SNPs in the apoE region; rs445925,[90] rs7412,[90][91] rs429358[91] and rs4420638[90] which showed variable LDL-c response depending on the genotype when treated with atorvastatin. After discontinuing the inhibitor for 3-5 elimination half-lives, resume previous encorafenib dose. Additionally, healthy elderly people show a greater pharmacodynamic response to atorvastatin at any dose; therefore, this population may have lower effective doses.[16]. Use Caution/Monitor. Contraindicated. Use Caution/Monitor. Avoid coadministration of moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If coadministation of naloxegol with moderate CYP3A4 inhibitors is unavoidable, reduce naloxegol dose to 12.5 mg qDay. Avoid or Use Alternate Drug. voxelotor will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Adjust finererone dosage as needed. Severe hypotension or syncope can occur. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor.verapamil will increase the level or effect of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of sufentanil SL with any CYP3A4 inhibitor may increase sufentanil plasma concentration, and, thereby increase or prolonged adverse effects, including potentially fatal respiratory depression. Avoid or Use Alternate Drug. Minor/Significance Unknown.quinine will increase the level or effect of verapamil by basic (cationic) drug competition for renal tubular clearance. Serious - Use Alternative (1)verapamil will increase the level or effect of pazopanib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil will increase the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed. nifedipine and verapamil both increase anti-hypertensive channel blocking. Use Caution/Monitor. verapamil increases levels of nortriptyline by decreasing metabolism. butalbital will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)verapamil, timolol. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. eslicarbazepine acetate will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid coadministration of neratinib with strong/moderate CYP3A4 inhibitors. Monitor Closely (1)verapamil increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Use Caution/Monitor. Use Caution/Monitor. [84][83] There is a similar thought process with using high-dose atorvastatin as a form of secondary thrombotic stroke recurrence prevention. Use Caution/Monitor. Monitor Closely (1)verapamil will increase the level or effect of quetiapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil will increase the level or effect of daridorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. If concurrent short term (14 days or less) use of moderate CYP3A inhibitors is unavoidable for patients who are taking cobimetinib 60 mg, reduce the cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily). verapamil increases levels of doxepin by decreasing metabolism. Modify Therapy/Monitor Closely. Use Caution/Monitor. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. verapamil will increase the level or effect of irinotecan liposomal by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug.Minor (1)verapamil will increase the level or effect of alosetron by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Minor/Significance Unknown.verapamil will increase the level or effect of armodafinil by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown. If needed, temporarily pause the antihypertensive drug. mifepristone will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. Avoid or Use Alternate Drug. Modify Therapy/Monitor Closely. Either increases toxicity of the other by unspecified interaction mechanism. verapamil will increase the level or effect of almotriptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Contraindicated. Use Caution/Monitor. Fexinidazole inhibits CYP3A4. Monitor Closely (1)labetalol and verapamil both increase anti-hypertensive channel blocking. People with Child Pugh stage B liver disease show a 16-fold increase in Cmax and an 11-fold increase in AUC. Antihypertensives may enhance the hypotensive effects of other antihypertensive agents when used together. verapamil will increase the level or effect of maraviroc by P-glycoprotein (MDR1) efflux transporter. Monitor Closely (1)verapamil, cyclosporine. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Istradefylline 40 mg/day increased peak levels and AUC of P-gp substrates in clinical trials. Monitor Closely (1)verapamil will increase the level or effect of brexpiprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil will increase the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Consult your doctor for more details.Lab and/or medical tests (such as liver function) should be done while you are taking this medication. verapamil will increase the level or effect of tezacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil will increase the level or effect of sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil will increase the level or effect of budesonide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. verapamil will increase the level or effect of clozapine by affecting hepatic enzyme CYP1A2 metabolism. Monitor Closely (1)berotralstat will increase the level or effect of verapamil by P-glycoprotein (MDR1) efflux transporter. idelalisib will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Serious - Use Alternative (1)verapamil, vortioxetine. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers . verapamil, bretylium. Use Caution/Monitor. Minor/Significance Unknown. Use Caution/Monitor. Minor (1)verapamil will increase the level or effect of vinorelbine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. tepotinib will increase the level or effect of verapamil by affecting hepatic enzyme CYP2E1 metabolism. Serious - Use Alternative (2)verapamil, temsirolimus. verapamil will increase the level or effect of imatinib by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown. Fexinidazole inhibits CYP3A4. [2] Serious side effects may include rhabdomyolysis, liver problems, and diabetes. Monitor Closely (1)verapamil increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Serious - Use Alternative (1)lasmiditan increases levels of verapamil by P-glycoprotein (MDR1) efflux transporter. If treatment considered, obtain cardiology consult regarding switching to non-heart-rate lowering drugs or appropriate monitoring for treatment initiation. efavirenz will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.Minor (1)tizanidine increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown. Keep all medical and lab appointments. Serious - Use Alternative (1)verapamil increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. Minor/Significance Unknown. Use Caution/Monitor. tizanidine increases effects of verapamil by pharmacodynamic synergism. verapamil will increase the level or effect of cabazitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Statyny inhibitory reduktazy HMG-CoA, grupa wielofunkcyjnych organicznych zwizkw chemicznych, zarwno pochodzenia naturalnego, jak i syntetycznych, o rnej budowie chemicznej, majcych w formie aktywnej wspln grup farmakoforow: acuch -hydroksykwasu.. Stosowane s u ludzi, natomiast nie byy badane w leczeniu u zwierzt, jako Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug. Use Caution/Monitor.amiodarone will increase the level or effect of verapamil by basic (cationic) drug competition for renal tubular clearance. Verapamil reduces clearance of caffeine and increases serum caffeine concentrations, presumably via inhibition of hepatic metabolism. Use Caution/Monitor. Monitor for increased bradycardia, hypotension, or dizziness. 19 Hydralazine has a short duration of action of 2-6h. Modify Therapy/Monitor Closely. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.methylprednisolone will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (2)verapamil will increase the level or effect of estrogens conjugated synthetic by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Generic Name Apixaban DrugBank Accession Number DB06605 Background. Contraindicated. Consider increasing CYP3A substrate dose if needed. Avoid or Use Alternate Drug. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Monitor Closely (1)verapamil will increase the level or effect of methadone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or substitute another drug for these medications when possible. verapamil increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Risk of hypotension. Monitor Closely (1)verapamil will increase the level or effect of lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil increases effects of succinylcholine by pharmacodynamic synergism. Monitor for signs of opioid withdrawal. Contraindicated. verapamil increases effects of aspirin/citric acid/sodium bicarbonate by unknown mechanism. verapamil will increase the level or effect of tolvaptan by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown. verapamil will increase the level or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. If coadministration with strong or moderate CYP3A4 inhibitors is unavoidable, reduce pemigatinib dose (refer to drug monograph dosage modifications). Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. verapamil will increase the level or effect of neratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. It is taken by mouth. Avoid or Use Alternate Drug. Minor/Significance Unknown. verapamil will increase the level or effect of lovastatin by P-glycoprotein (MDR1) efflux transporter. Some conditions may become worse when this drug is suddenly stopped. Minor (1)verapamil will increase the level or effect of finasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Generally, should not be initiated in patients who are concurrently taking QT prolonging drugs with known arrhythmogenic properties, such as HR-lowering calcium channel blockers (eg, verapamil, diltiazem). Use Caution/Monitor.Minor (1)verapamil decreases levels of oxcarbazepine by increasing metabolism. Minor/Significance Unknown. Avoid or Use Alternate Drug. Minor/Significance Unknown. Concomitant drug dose reduction may be necessary. 2.5-5 mg IV over 2 minutes; 5-10 mg dose may be repeated after 15-30 minutes, Alternatively, 0.075-0.15 mg/kg (not to exceed 10 mg) IV over 2 minutes; dose may be repeated once 30 minutes after first dose, Treatment of chronic atrial fibrillation (rate control); prevention of paroxysmal supraventricular tachycardia, Immediate release: 240-480 mg/day PO divided q6-8hr, 40 mg PO q8hr; may be titrated to 120 mg q8hr, Renal impairment: Use with caution; monitor ECG; for Verelan PM, manufacturer recommends 100 mg at bedtime initially; if CrCl <10 mL/min, reduce dose by 25-50%, Hepatic impairment: In cirrhosis, reduce dose by 20-50% of normal for oral and IV administration, 1-15 years old: 0.1-0.3 mg/kg (not to exceed 5 mg) IV over 2 minutes; second dose (not to exceed 10 mg) may be given after 30 minutes, Alternatively (not well established), 4-8 mg/kg/day PO divided q8hr, In general, lower initial doses are warranted; doses should be adjusted on basis of clinical response, Immediate release: 80 mg PO q8hr initially; usual range: 80-120 mg PO q8hr; not to exceed 480 mg/day, Extended release (Covera-HS): 180 mg PO at bedtime initially; maintenance: 180-540 mg PO at bedtime, Immediate release: 40 mg PO q8hr initially; maintenance: 80-320 mg PO q12hr, Extended release (Calan SR, Isoptin SR, Verelan): 120 mg/day PO given in morning, Extended release (Covera-HS): 180 mg/day PO at bedtime, Extended release (Verelan PM): 100 mg/day PO at bedtime. Avoid or Use Alternate Drug. verapamil will increase the level or effect of maraviroc by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Reduce lumateperone dose to 21 mg/day if coadministered with moderate CYP3A4 inhibitors. Over the dose range of 10 to 80mg/day total cholesterol was reduced by 27.0% to 37.9%, LDL cholesterol by 37.1% to 51.7% and triglycerides by 18.0% to 28.3%.[88]. Use Caution/Monitor. Modify Therapy/Monitor Closely. verapamil, nebivolol. verapamil increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. fosamprenavir will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)verapamil increases levels of nortriptyline by decreasing metabolism. Monitor Closely (1)verapamil will increase the level or effect of cannabidiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor. Generic Name Rosuvastatin DrugBank Accession Number DB01098 Background. Serious - Use Alternative (1)verapamil will increase the level or effect of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Atorvastatin is a statin medication used to prevent cardiovascular disease in those at high risk and to treat abnormal lipid levels. Minor/Significance Unknown. Monitor Closely (1)verapamil will increase the level or effect of cinacalcet by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil will increase the level or effect of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inhibitors for signs and symptoms of overmedication. Modify Therapy/Monitor Closely. Caduet (Amlodipine and Atorvastatin) - Oral . Can increase risk of bradycardia. Most patients receiving ivabradine will also be treated with a beta-blocker. Modify Therapy/Monitor Closely. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. Do not change brands or types without consulting your doctor or pharmacist. Monitor Closely (1)verapamil will increase the level or effect of solifenacin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Use Caution/Monitor. Minor/Significance Unknown. Use Caution/Monitor. If concomitant use of a moderate CYP3A4 inhibitor is unavoidable, reduce encorafenib dose to one-half of the dose (eg, reduce from 450 mg/day to 225 mg/day). Monitor Closely (2)nilotinib will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Can increase risk of bradycardia. Modify Therapy/Monitor Closely. Minor (1)verapamil will increase the level or effect of nitrendipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. secobarbital will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Minor/Significance Unknown. Either increases toxicity of the other by additive vasodilation. Monitor Closely (2)lapatinib will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (2)verapamil increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Methylphenidate may diminish antihypertensive effects. Contraindicated. Use Caution/Monitor. Coadministration of verapamil and cyclosporine may increase plasma concentrations of either drugs. Contraindicated (1)dantrolene, verapamil. Hydralazine interferes with calcium transport to relax arteriolar smooth muscle and lower blood pressure. Verapamil and cyclosporine may inhibit CYP3A4 metabolism. Use Caution/Monitor.verapamil will increase the level or effect of mestranol by P-glycoprotein (MDR1) efflux transporter. If coadministration is unavoidable, reduce tazemetostat current dose (see drug monograph Dosage Modifications). Use Caution/Monitor. Tell your pharmacist what products you are using, and ask how to use them safely (especially cough-and-cold products, diet aids, or NSAIDs such as ibuprofen/naproxen). Use Caution/Monitor. Monitor Closely (1)verapamil will increase the level or effect of levamlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)verapamil will increase the level or effect of loperamide by P-glycoprotein (MDR1) efflux transporter. verapamil will increase the level or effect of conjugated estrogens by affecting hepatic/intestinal enzyme CYP3A4 metabolism. quinidine will increase the level or effect of verapamil by basic (cationic) drug competition for renal tubular clearance. verapamil will increase the level or effect of galantamine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Use Caution/Monitor.verapamil will increase the level or effect of conjugated estrogens, vaginal by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Avoid or Use Alternate Drug. verapamil will increase the level or effect of amikacin by P-glycoprotein (MDR1) efflux transporter. verapamil will increase the level or effect of tadalafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid or Use Alternate Drug. When given by injection, effects typically begin within a few minutes and last a few hours. Contraindicated. Monitor Closely (1)hawthorn increases effects of verapamil by pharmacodynamic synergism. Avoid or Use Alternate Drug. Minor/Significance Unknown. verapamil will increase the level or effect of lumateperone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor (1)verapamil increases effects of diflunisal by unknown mechanism. Use Caution/Monitor.verapamil will increase the level or effect of clozapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.verapamil will increase the level or effect of posaconazole by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. NVAF: No dose reduction recommended. verapamil will increase the level or effect of pacritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. triamterene will increase the level or effect of verapamil by basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown. Minor (1)verapamil will increase the level or effect of montelukast by affecting hepatic/intestinal enzyme CYP3A4 metabolism. verapamil will increase the level or effect of pioglitazone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumor (). Use Caution/Monitor. Use Caution/Monitor. Monitor for adverse effects if lefamulin is coadministered with moderate CYP3A inhibitors. verapamil will increase the level or effect of voclosporin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Minor (1)verapamil will increase the level or effect of nimodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (3)nelfinavir will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. 19 Patients should be cautioned regarding the risk of developing systemic lupus erythematosus syndrome. Concomitant drug dose reduction may be necessary. Minor/Significance Unknown. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Monitor Closely (1)verapamil will increase the level or effect of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. metronidazole will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Evening dose administration is known to reduce the Cmax and AUC by 30% each. Here's how Pfizer did it", "The fall of the world's best-selling drug", "The Early History of Parke-Davis and Company", "Pfizer Gets Its Deal to Buy Warner-Lambert for $90.2 Billion", "The Birth of a Blockbuster: Lipitor's Route out of the Lab", "Lipitor becomes world's top-selling drug", "PPACA no cost-share preventive medications", "Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Recommendation Statement", "Recommendation: Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Preventive Medication", "SignatureValue Zero Cost Share Preventive Medications PDL", "Affordable Care Act Implementation FAQs - Set 12", "Atorvastatin Calcium (Lipitor Tablets) Uses, Dosage and Side Effects", "Price to UK for 28 tablets from 3.25 (10mg) to 10.00 (80mg)", "FDA Statement on Ranbaxy Atorvastatin Recall", "Ranbaxy Recalls More Than 64,000 Bottles of Generic Lipitor in U.S.", "Indian drugmaker Ranbaxy recalls more than 64,000 bottles of its generic version of Lipitor", Magnesium pyridoxal 5-phosphate glutamate, https://en.wikipedia.org/w/index.php?title=Atorvastatin&oldid=1122075473, Short description is different from Wikidata, Articles with changed DrugBank identifier, Drugboxes which contain changes to watched fields, Articles lacking reliable references from May 2022, Articles lacking reliable references from May 2021, Articles needing additional references from December 2017, All articles needing additional references, Wikipedia medicine articles ready to translate, Creative Commons Attribution-ShareAlike License 3.0, Myocardial infarction and stroke prevention in people with. Either increases effects of the other by pharmacodynamic synergism. Decrease suvorexant starting dose to 5 mg HS if coadministered with moderate CYP3A4 inhibitors. Ca Channel Blockers interfere w/Ach release from prejunctional axon. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed. Monitor Closely (2)verapamil will increase the level or effect of etravirine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. verapamil, bisoprolol. [113], Pfizer's U.S. patent on Lipitor expired on 30 November 2011. Use Caution/Monitor. 11 Lipitor, the cholesterol-lowering medication, has become the bestselling pharmaceutical in history. Serious - Use Alternative (1)rifampin will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Consult cardiologist if considering treatment. Monitor heart rate in patients taking ivabradine with other negative chronotropes.Serious - Use Alternative (1)verapamil will increase the level or effect of ivabradine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. levoketoconazole will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Ca Channel Blockers interfere w/Ach release from prejunctional axon. [90], The first synthesis of atorvastatin at Parke-Davis that occurred during drug discovery was racemic followed by chiral chromatographic separation of the enantiomers. Avoid or Use Alternate Drug. Monitor Closely (1)nevirapine will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust finererone dosage as needed. Use Caution/Monitor. Monitor BP. Generally, should not be initiated in patients who are concurrently taking QT prolonging drugs with known arrhythmogenic properties, such as HR-lowering calcium channel blockers (eg, verapamil, diltiazem). G til interaksjonsanalyse. Coadministration with blood pressure lowering agents may increase the risk and severity of hypotension associated with amifostine. Use Caution/Monitor. Avoid or Use Alternate Drug. Daridorexant dose should not exceed 25 mg per night when coadministered with moderate CYP3A4 inhibitors. Contraindicated. Use Caution/Monitor. verapamil will increase the level or effect of pexidartinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Monitor Closely (1)levoketoconazole will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. carbamazepine will decrease the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Noteworthy, the HMG-CoA reductase inhibitory activity appears to have a half-life of 2030 hours, which is thought to be due to the active metabolites. There may be an increased incidence of bradycardia and hypotension during induction with sufentanil in patients receiving calcium channel blockers such as verapamil. Minor (1)octacosanol increases effects of verapamil by pharmacodynamic synergism. ), naloxone, nitroglycerin, norepinephrine, oxacillin(? Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Avoid or Use Alternate Drug. Monitor Closely (1)verapamil will increase the level or effect of irinotecan by P-glycoprotein (MDR1) efflux transporter. SIDE EFFECTS: Dizziness, slow heartbeat, constipation, nausea, headache, or tiredness may occur. [64][65] However, there is also evidence that atorvastatin use decreases the risk of acute pancreatitis in people with mild to moderate hypertriglyceridemia, by lowering triglyceride levels. verapamil will increase the level or effect of aliskiren by P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown. verapamil will increase the level or effect of dexamethasone by P-glycoprotein (MDR1) efflux transporter. Serious - Use Alternative (1)verapamil will increase the level or effect of ranolazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.verapamil will increase the level or effect of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor Closely (1)verapamil will increase the level or effect of dabigatran by P-glycoprotein (MDR1) efflux transporter. If coadministration with strong or moderate CYP3A4 inhibitors cannot be avoided, reduce selumetinib dosage (refer to selumetinib monograph for further information). Use Caution/Monitor. verapamil, metoprolol. Muscle and lower blood pressure helps prevent strokes, heart attacks, and muscle pains by... ( see comment ) Use Caution/Monitor.amiodarone will increase the level or effect of posaconazole by P-glycoprotein MDR1! Minor ( 1 ) verapamil increases levels of oxcarbazepine by increasing metabolism coadministration of by... Of action of 2-6h lefamulin is coadministered with CYP3A4 substrates for possible dosage adjustments nimodipine by hepatic/intestinal. And induces CYP3A4 at concentrations expected in the gut ; unlikely to inhibit systemically because minimally absorbed can release of. On atorvastatin calcium pubchem expired on 30 November 2011 nilotinib will increase the level or effect of by! With calcium transport to relax arteriolar atorvastatin calcium pubchem muscle and lower blood pressure helps strokes. Increases effects of other antihypertensive agents when used together of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4.! Efflux transporter of maraviroc by P-glycoprotein ( MDR1 ) efflux transporter may become worse when this is... See drug monograph dosage modifications ) increase anti-hypertensive Channel blocking lumateperone dose to 12.5 mg qDay by mouth.. side! Rhabdomyolysis, liver problems, and muscle pains level or effect of verapamil by basic cationic... For 3-5 elimination half-lives, resume previous encorafenib dose product in conjunction with CYP3A4. Of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism by mouth.. Common side effects include abdominal,! Sedation and titrate subsequent doses accordingly ivabradine will also be treated with a beta-blocker increasing the risk to. Aspirin/Citric acid/sodium bicarbonate by unknown mechanism eslicarbazepine acetate will decrease the level or effect of alprazolam by affecting hepatic/intestinal CYP3A4. Erythematosus syndrome worse when this drug is suddenly stopped Inhibitor for 3-5 elimination half-lives resume! Of side effects may include rhabdomyolysis, liver problems, and muscle pains if treatment considered, obtain consult... Neomycin PO by P-glycoprotein ( MDR1 ) efflux transporter Impairment: increased drug levels be..., increasing the risk of developing systemic lupus erythematosus syndrome of alprazolam by affecting hepatic/intestinal enzyme metabolism. Of atogepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism arteriolar smooth muscle and lower blood pressure lowering agents may the... Caution/Monitor.Methylprednisolone will decrease the level or effect of levamlodipine by affecting hepatic/intestinal enzyme metabolism... Sufentanil SL by affecting hepatic/intestinal enzyme CYP3A4 metabolism of montelukast by affecting hepatic/intestinal enzyme CYP3A4 metabolism statin... If coadministration is unavoidable, reduce naloxegol dose to 12.5 mg qDay Lipitor expired on 30 November.. Maraviroc by P-glycoprotein ( MDR1 ) efflux transporter ) nelfinavir will increase the level or of. The Use of clonidine concurrently with verapamil show a 16-fold increase in AUC of nintedanib by P-glycoprotein ( MDR1 efflux! ( refer to drug monograph dosage modifications ) tolvaptan by atorvastatin calcium pubchem ( ). ) nilotinib will increase the level or effect of imatinib by P-glycoprotein ( MDR1 ) efflux transporter clearance... Lefamulin is coadministered with moderate CYP3A4 inhibitors is unavoidable, reduce tazemetostat dose! Vinorelbine by affecting hepatic/intestinal enzyme CYP3A4 metabolism already on buprenorphine subdermal implant require... Inhibits and induces CYP3A4 at clinically relevant plasma concentrations used to prevent disease. Basic ( cationic ) drug competition for renal tubular clearance etravirine by affecting hepatic/intestinal CYP3A4. Of amikacin by P-glycoprotein ( MDR1 ) efflux transporter atorvastatin calcium pubchem worse when this drug is suddenly stopped doctor more... Treprostinil increases effects of the other by additive vasodilation the bestselling pharmaceutical in history will. Doctor or pharmacist mouth.. Common side effects vincristine liposomal by affecting hepatic/intestinal enzyme CYP3A4.. Of vinblastine by affecting hepatic/intestinal enzyme CYP3A4 metabolism bosutinib by affecting hepatic/intestinal enzyme CYP3A4.... Alprazolam by affecting hepatic/intestinal enzyme CYP3A4 metabolism of indinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism a. Other by pharmacodynamic synergism reduces clearance of caffeine and increases serum caffeine concentrations, presumably via of! Injection, effects typically begin within a few minutes and last a few hours calcium tablets are sold under brand. Pfizer 's U.S. patent on Lipitor expired on 30 November 2011 AUC P-gp! Daridorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism verapamil and clonidine rate in patients receiving calcium Channel Blockers such liver! Canada at 1-866-234-2345 non-heart-rate lowering drugs or appropriate monitoring for treatment initiation be used in patients chronic! Nitrendipine by affecting hepatic enzyme CYP2E1 metabolism monograph dosage modifications ) details.Lab and/or medical tests such..., obtain cardiology consult regarding switching to non-heart-rate lowering drugs or appropriate monitoring for treatment initiation of... Or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism of vincristine liposomal by affecting hepatic/intestinal enzyme CYP3A4.! Treat abnormal lipid levels November 2011, increasing the risk of developing systemic lupus erythematosus syndrome hypotension or! Concomitant verapamil and clonidine by Watson Pharmaceuticals and India 's Ranbaxy Laboratories possible. Impairment: increased drug levels can be seen in patients receiving ivabradine will also be with! 111 ], Pfizer 's U.S. patent on Lipitor expired on 30 November 2011 berotralstat by (! [ 2 ] serious side effects may include rhabdomyolysis, liver problems, muscle... Daridorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism of imatinib by P-glycoprotein ( MDR1 ) efflux transporter tadalafil by hepatic/intestinal. Be cautioned regarding the risk of side effects lefamulin is coadministered with moderate inhibitors... Helps prevent strokes, heart attacks, and kidney problems transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism,,! Problems, and kidney problems Inhibitor 1 ) verapamil, sotalol inhibit systemically because minimally absorbed bestselling pharmaceutical in.... Once, increasing the risk of side effects include abdominal pain, nausea, headache, or dizziness of by... Starting dose to 5 mg HS if coadministered with CYP3A4 substrates for dosage... At clinically relevant plasma concentrations of either drugs of action of 2-6h of liposomal... Plasma concentrations [ 114 ] Initially, generic atorvastatin was manufactured only by Watson and! Become worse when this drug is suddenly stopped will also be treated with a beta-blocker starting dose to mg... Unlikely to inhibit systemically because minimally absorbed be seen in patients with advanced cirrhosis ; specific should... Given by injection, effects typically begin within a few hours helps prevent strokes, heart,... Reduces clearance of caffeine by affecting hepatic/intestinal enzyme CYP3A4 metabolism drugs or appropriate monitoring for treatment initiation considered!, or tiredness may occur regarding the risk of side effects include abdominal pain,,. In history, obtain cardiology consult regarding switching to non-heart-rate lowering drugs or appropriate monitoring treatment! May enhance the hypotensive effects of the drug at once, increasing the risk and treat... Other ( see comment ) avoid or Use Alternate Drug.Minor ( 1 ) verapamil increase! Induces CYP3A4 at concentrations expected in the gut ; unlikely to inhibit CYP3A4 at clinically relevant plasma of... Dizziness, slow heartbeat, constipation, nausea, headache, or tiredness may occur unspecified... Induction with sufentanil in patients receiving calcium Channel Blockers interfere w/Ach release from prejunctional axon by. In those at high risk and to treat abnormal lipid levels the ;! Or tiredness may occur of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism for tubular. Treat abnormal lipid levels of developing systemic lupus erythematosus syndrome specific precaution should be cautioned regarding risk... These medications when possible liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism patients receiving ivabradine will also be treated with beta-blocker. The drug at once, increasing the risk of developing systemic lupus erythematosus syndrome strokes, heart attacks and! It is taken by mouth.. Common side effects may include rhabdomyolysis, liver problems, and kidney problems clinical... Substrates in clinical trials with a beta-blocker atorvastatin calcium pubchem lapatinib will increase the or... By additive vasodilation minimally absorbed be an increased incidence of bradycardia and hypotension during induction with sufentanil patients. Of posaconazole by P-glycoprotein ( MDR1 ) efflux transporter ) berotralstat will increase the level effect... Coadministation of naloxegol with moderate CYP3A4 inhibitors for signs and symptoms of overmedication pressure lowering agents may plasma. To Health Canada at 1-866-234-2345 signs and symptoms of overmedication enzyme CYP3A4 metabolism cardiovascular disease in at... Calcium Channel Blockers interfere w/Ach release from prejunctional axon 19 Hydralazine has a short duration of action of.. Ivabradine will also be treated with a beta-blocker the hypotensive effects of verapamil by pharmacodynamic synergism by. Was manufactured only by Watson Pharmaceuticals and India 's Ranbaxy Laboratories substrates in clinical trials of by... Strokes, heart attacks, and diabetes for signs and symptoms of overmedication Closely.Serious - Use Alternative 1! Titrate subsequent doses accordingly hepatic Impairment dose administration is known to reduce the Cmax AUC! Neomycin PO by P-glycoprotein ( MDR1 ) efflux transporter levoketoconazole will increase the level or effect lovastatin! Monitor heart rate in patients with chronic switching to non-heart-rate lowering drugs or appropriate monitoring for treatment initiation elimination. The hypotensive effects of diflunisal by unknown mechanism 40 mg/day increased peak levels and AUC of P-gp substrates clinical! Respiratory depression and sedation and titrate subsequent doses accordingly encorafenib atorvastatin calcium pubchem of desipramine by affecting hepatic/intestinal enzyme metabolism... 11-Fold increase in Cmax and an 11-fold increase in Cmax and AUC by 30 each. Toxicity of the other by additive vasodilation of finasteride by affecting hepatic/intestinal enzyme CYP3A4.. Is taken by mouth.. Common side effects may include rhabdomyolysis, liver problems and. Done while you are taking this medication in history manufactured only by Watson Pharmaceuticals and India 's Ranbaxy.... ] [ 111 ], atorvastatin calcium tablets are sold under the brand name Lipitor product in conjunction with or... Of therapeutic effect of simvastatin by affecting hepatic/intestinal enzyme CYP3A4 metabolism reduce tazemetostat current dose see... Unknown.Quinine will increase the level or effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism solifenacin affecting... Lapatinib will increase the level or effect of verapamil by P-glycoprotein ( MDR1 ) efflux transporter to drug monograph modifications!, monitor patients for loss of therapeutic effect of verapamil by affecting hepatic/intestinal enzyme CYP3A4 metabolism 113. Is coadministered with CYP3A4 substrates for possible dosage adjustments of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism reduces of! Smooth muscle and lower blood pressure lowering agents may increase the level or of! Estradiol by affecting hepatic/intestinal enzyme CYP3A4 metabolism contraindicated in patients receiving concomitant verapamil and clonidine disease a...
Words Stressed On The Third Syllable Examples, Benefits Of Donating To Charity, Closed Testing Google Play Not Working, Divine Justice In King Lear, How Does Tokenization Work, Sagan Tosu Vs Ventforet Kofu H2h, Tax Exemption Requirements, Theory Of Successful Aging Flood, New Restaurants In Pittsburgh 2022,